Regulation of sclerostin in glucocorticoid-induced osteoporosis (GIO) in mice and humans

Sylvia Thiele1,2, Anke Hannemann3, Maria Winzer1,2, Ulrike Baschant1,2, Heike Weidner1,2, Matthias Nauck3, Rajesh V Thakker4, Martin Bornhäuser5,6, Lorenz C Hofbauer1,2,6 and Martina Rauner1,2

1Department of Medicine III, Technische Universität Dresden, Dresden, Germany
2Center for Healthy Aging, Technische Universität Dresden, Dresden, Germany
3Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany
4Academic Endocrine Unit, Radcliffe Department of Medicine University of Oxford, Oxford Centre for Diabetes, Endocrinology, and Metabolism, Churchill Hospital, Oxford, UK
5Department of Medicine I, Technische Universität Dresden, Dresden, Germany
6DFG Research Center and Cluster of Excellence for Regenerative Therapies, Technical University, Dresden, Germany

Correspondence should be addressed to M Rauner: martina.rauner@ukdd.de

Abstract

Glucocorticoids (GC) are used for the treatment of inflammatory diseases, including various forms of arthritis. However, their use is limited, amongst others, by adverse effects on bone. The Wnt and bone formation inhibitor sclerostin was recently implicated in the pathogenesis of GC-induced osteoporosis. However, data are ambiguous. The aim of this study was to assess the regulation of sclerostin by GC using several mouse models with high GC levels and two independent cohorts of patients treated with GC. Male 24-week-old C57BL/6 and 18-week-old DBA/1 mice exposed to GC and 12-week-old mice with endogenous hypercortisolism displayed reduced bone formation as indicated by reduced levels of P1NP and increased serum sclerostin levels. However, expression of sclerostin in femoral bone tissue and GC-treated bone marrow stromal cells, however, was not consistently altered. In contrast, GC dose- and time-dependently suppressed sclerostin at mRNA and protein levels in human mesenchymal stromal cells, and this effect was GC receptor dependent. In line with the human cell culture data, patients with rheumatoid arthritis (RA, n = 101) and polymyalgia rheumatica (PMR, n = 21) who were exposed to GC had lower serum levels of sclerostin than healthy age- and sex-matched controls (−40%, P < 0.01 and −26.5%, P < 0.001, respectively). In summary, sclerostin appears to be differentially regulated by GC in mice and humans as it is suppressed by GCs in humans but is not consistently altered in mice. Further studies are required to delineate the differences between GC regulation of sclerostin in mice and humans and assess whether sclerostin mediates GC-induced osteoporosis in humans.

Introduction

Glucocorticoids (GCs) are effective drugs in the treatment of immune-mediated diseases, including rheumatoid arthritis or allergic diseases such as asthma. However, their administration is often accompanied by adverse effects on bone mass and strength, resulting in increased osteoporotic fracture probability (1). Chronic GC therapy leads to decreased bone mineral density, and up to 50% of treated patients experience vertebral fractures (2). The complex pathogenesis of glucocorticoid-induced osteoporosis (GIO) involves many organ systems. At the skeletal level,
GCs stimulate osteoclastogenesis and profoundly inhibit bone formation (3, 4). While an increased receptor activator of NF-κB ligand (RANKL)/osteoprotegerin (OPG) ratio in osteoblastic cells promotes osteoclastogenesis, inhibition of osteoblast differentiation, reduced matrix production, increased osteoblast and osteocyte apoptosis and increased autophagy further seem to contribute to GIO (5, 6, 7, 8).

To gain further insight into the underlying mechanisms of GC-induced suppression of bone formation, we focused on the Wnt signaling pathway as it plays an important role during osteoblast development. In our previous work, we showed that the Wnt inhibitor Dickkopf-1 (Dkk-1) is increased by GCs in mice and osteoblast cell cultures. Moreover, this regulation is dependent on the GC receptor (GR) (9). In vivo studies indicate that suppression of Dkk-1 using RNA interference or knockout of Dkk-1 in osteoblasts and osteocytes prevents GC-induced bone loss in mice. Thus, the GC-mediated induction of Dkk-1 in osteogenic cells is a critical pathogenic mechanism of GIO (S Thiele, U Baschant, LC Hofbauer, M Rauner, unpublished observations; 10). Recently, studies have proposed a contribution of another Wnt inhibitor, sclerostin, to the pathophysiology of GIO. However, data are contradictory (11, 12, 13, 14). Sclerostin is expressed mostly by osteocytes, making it a favorable candidate to specifically target Wnt signaling in the bone compartment (15, 16, 17). However, SOST expression has also been reported in other cell types, for example, hypertrophic chondrocytes and cementocytes (18). Sclerostin-deficient mice display increased bone formation, bone mass and strength, underlining its negative regulation of bone homeostasis (19). Blocking sclerostin using specific antibodies has already been shown to restore bone mass in conditions of estrogen deficiency (20), hyperthyroidism (21), aging (22), disuse (23) and colitis (24) in rodents. Therefore, the aim of this study was to comprehensively investigate the regulation of sclerostin by GCs in vivo and in vitro in mice and in humans to evaluate its potential as therapeutic target to treat GIO.

**Materials and methods**

**Induction of glucocorticoid-induced bone loss in mice**

Male C57BL/6 JRj and DBA/1JRj mice were purchased from Janvier (Saint Berthevin Cedex, France) and housed under institutional guidelines. All mice (n = 10) were fed a standard diet with water ad libitum and were kept in a 12:12h light:darkness cycle at room temperature in filter top cages with cardboard houses as enrichment. The local animal care committee (Landesdirektion Sachsen) approved all animal procedures. To induce GC-induced bone loss (long-term approach), 6-month-old male C57BL/6 mice were implanted with 60-day slow-release pellets (Innovative Research of America, Sarasota, FL, USA) containing either vehicle or prednisolone (PRED; 7.5 mg) for 4 weeks. Mice were randomly assigned to the groups. For short-term GC treatment, 18-week-old male DBA/1 mice received either PBS or dexamethasone (DEX; 100 µg/mouse) intraperitoneally, every second day for 10 days. After the respective treatment period, mice were killed to examine the effects on the skeleton.

In addition, a mouse model for Cushing’s syndrome due to an N-ethyl-N-nitrosourea (ENU) induced mutation at −120bp of the promoter region of the corticotropin releasing hormone gene (Crh<sup>120/+</sup>), that resulted in an increased luciferase reporter activity and is thus a gain-of-function mutation, was used as an endogenous model for GC excess (25). Male Crh<sup>−120/+</sup> mice (n = 5) and their littermate controls used in this study are congenic on a C57BL/6j background and were housed in the Mary Lyon Centre at MRC Harwell. Mice were kept and studied in accordance with UK Home Office legislation and local ethical guidelines issued by the Medical Research Council (Responsibility in the Use of Animals for Medical Research, July 1993; home office license 30/2642). Mice were kept under controlled light (light 07:00–19:00 h, dark 19:00–07:00 h), temperature (21 ± 2°C) and humidity (55 ± 10%) conditions. They had free access to water (9–13 ppm chlorine) and were fed ad libitum. After 12 weeks, mice were killed to collect the serum.

**Culture of human and murine bone marrow-derived osteoblasts**

Primary human bone marrow stromal cells (hMSC) were collected from healthy donors (aged 22–49 years, mixed gender) following Institutional Review Board approval by the Technische Universität Dresden and obtaining written informed consent. The study was approved by the Institutional Review Board of the Technische Universität Dresden. The cells were cultured in DMEM (Thermo Fisher Scientific) with 10% FCS (Biochrom, Berlin, Germany) and 1% penicillin/streptomycin (P/S; Thermo Fisher Scientific) and were used in passages 3–5 (26). To induce osteogenic differentiation, 70% confluent cells were switched to basal medium supplemented with 100 µM ascorbate phosphate, 5 mM b-glycerol phosphate and 10 nM DEX (all from Sigma-Aldrich) for 21 days.
Before treatment, cells were switched to starving media overnight and then treated with DEX (Sigma-Aldrich) at concentrations as indicated in the appropriate figure for 48 h and 72 h, respectively.

For the culture of primary murine BMSC, femora and tibiae from WT C57BL/6 mice were flushed and seeded at a density of 1 × 10^6 cells per cm^2 in DMEM supplemented with 10% FCS and 1% P/S. To induce osteogenic differentiation, 70% confluent cells were switched to basal medium supplemented with 100μM ascorbate phosphate and 10mM b-glycerol phosphate for 21 days. Before treatment, cells were switched to starving media overnight and then treated with 1 μM DEX for 48 h.

**Overexpression and knock-down experiments**

Overexpression of the GC receptor (GR) was induced in hMSCs using 1 μg GR plasmid-DNA (pcMX-HA-hGRalpha, kindly provided by Karolien De Bosscher, University of Gent, Belgium) and 3 μL of the transfection reagent Fugene HP (Roche). The plasmid-DNA was diluted in 100mL Opti-MEM (Gibco Life Technologies), and after 5 min of incubation at RT, Fugene HD was added and incubated for 20 min at RT. The transfection mixture was added drop-wise to 70% confluent cells seeded in 1 mL growth medium in a six-well plate and incubated for 48 h.

GR knockdown was performed using DharmaFECT (Thermo Fisher Scientific) and GR siRNA (s6187; Ambion Life Technologies). Nontargeting siRNA (Ambion Life Technologies) was used as control. DharmaFECT (transfection reagent) and siRNA were incubated in 100μL FCS-free Opti-MEM for 20 min at RT. Transfection mixture was added to a final concentration of 50nM to hMSC with P/S-free medium containing 10% FCS. Medium was changed after 6 h to stop the transfection.

**RNA isolation, RT, and real-time PCR**

RNA from human and murine BMSCs was isolated using Trifast (Peqlab, Erlangen, Germany) after washing twice with PBS. RNA isolation was performed according to the manufacturer’s protocol. Using Superscript II (Invitrogen), 500ng RNA were reverse transcribed and subsequently used for SYBR green-based real-time PCR reactions according to a standard protocol (Applied Biosystems). Primer sequences were human (hu) beta-actin (ACTB) forward (f): CCAACCGGCGAGAGATGA, hu ACTB reverse (r): CCAGAGGCGGACGGGATAG, murine (mu) Actb f: GATCTGGACACCCACCTCT, mu Actb r: GGGGTGTGTGAGGTCTCAAA, hu osteocalcin (bone gamma-carboxyglutamate protein (BGLAP)) f: tgagagccctcacactcctc, hu BGLAP r: accttgggtctgccctc, mu Bglap f: GCGCTCTGTTCTTCTACGAC, mu Bglap r: ACCTTATGCTCCCTCTGT, hu nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor; NR3C1) f: GCCGAGGGTTTTATCACCTG, hu NR3C1 r: CAGCTAACATCTCAGGAAT, hu SOST f: CACAGCCTCCGTGTAGTG, hu SOST r: ATTCCCGGGCATCATCCTG, mu Sost f: CCGAGAATGGGGACAGAC, mu Sost r: GTCAGGGAAGGCGGTAGTG. PCR conditions were 50°C for 2 min and 95°C for 10 min followed by 40 cycles with 95°C for 15 s and 60°C for 1 min. The melting curve was assessed using the following program: 95°C for 15 s, 60°C for 1 min and 95°C for 30 s. The results were calculated applying the ΔΔ-CT method and are presented in x-fold increase relative to beta-actin.

**Analysis of sclerostin and bone formation and resorption markers in the serum and supernatant**

Pro-collagen type 1 N-terminal peptide (P1NP; IDS Immunodiagnostics Systems GmbH, Frankfurt am Main, Germany) as well as sclerostin (ALPCO) were measured in the serum of mice using commercially available ELISAs. Sclerostin was measured in the cell culture supernatant of hMSC (Biomedica Medizinprodukte GmbH & Co KG, Vienna, Austria).

P1NP, osteocalcin and carboxy-terminal telopeptide of type I collagen (CTX) in humans were measured in serum samples on the IDS-iSYS Multi-Discipline Automated Analyser (Immunodiagnostic Systems Limited, Frankfurt am Main, Germany). Sclerostin concentrations in humans were measured in serum samples using the Biomedical sclerostin assay (Biomedical Medizinprodukte GmbH & Co KG).

**Study populations**

Serum samples from 101 patients with RA and 21 patients with polymyalgia rheumatica (PMR) were collected at the Division of Rheumatology at the Department of Medicine III at the Technische Universität Dresden. The median disease duration at the time point of blood collection was 4.76 years for RA and 1.31 years for PMR, respectively. RA was defined according to the 2010 ACR/EULAR and disease duration at the time point of blood collection was 4.76 years for RA and 1.31 years for PMR, respectively. RA was defined according to the 2010 ACR/EULAR and PMR according to the ACR/EULAR classification criteria. Characteristics of the patient cohorts are given in Tables 1 and 2. Forty of the RA patients received biologic disease-modifying anti-rheumatic drugs (DMARDs) with or
without combination with conventional basis therapy (traditional DMARDs), while 58 RA patients received non-biologic (traditional) DMARDs. Three patients with RA received no conventional basis therapy. At the time of analysis, 75 RA patients were in remission, while 20 showed a low disease activity and six a high disease activity (Table 1). Analysis of DXA measurements showed that 12 of the RA patients had osteoporosis (T-score $<-2.5$), while 33 displayed reduced bone density values (osteopenia, T-score $-1.0$ to $-2.5$) and 38 had normal bone density. For 18 of the patients we did not have data on bone mineral density.

Within the PMR group, two patients were treated with methotrexate (MTX) and four patients showed current disease activity at the time when the blood was collected (Table 2). Concerning the bone, we found that two of the patients displayed osteoporosis at the time of blood collection, while seven of the patients had osteopenia and six had normal T-scores. For four of the PMR patients we could not find DXA measurements. Age- (±3 years), sex-,

Table 1  Sclerostin in patients suffering from rheumatoid arthritis (RA) taking GC.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Controls</th>
<th>Cases</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease</td>
<td>RA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex, n</td>
<td>Male</td>
<td>101</td>
<td>1.00</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>69</td>
<td></td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
<td>61.0 (51.0–70.0)</td>
<td>61.0 (51.0–70.0)</td>
</tr>
<tr>
<td>Current smokers, n</td>
<td></td>
<td>34</td>
<td>1.00</td>
</tr>
<tr>
<td>BMI, kg/m$^2$</td>
<td></td>
<td>27.4 (24.9–30.0)</td>
<td>26.6 (24.9–30.1)</td>
</tr>
<tr>
<td>BMI categories, n</td>
<td></td>
<td>&lt;25 kg/m$^2$</td>
<td>26</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥25–29 kg/m$^2$</td>
<td>49</td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥30 kg/m$^2$</td>
<td>26</td>
</tr>
<tr>
<td>Treatment</td>
<td>No treatment</td>
<td>3</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>DMARDs</td>
<td>58</td>
<td></td>
</tr>
<tr>
<td></td>
<td>bDMARDs</td>
<td>40</td>
<td></td>
</tr>
<tr>
<td>CDAI</td>
<td></td>
<td>1.4 (0.4–3.0)</td>
<td>2.8 (1.0–6.0)</td>
</tr>
<tr>
<td>CRP, mg/L</td>
<td></td>
<td>2500 (1500–4775)</td>
<td>0 (0.0–5.0)</td>
</tr>
<tr>
<td>Auto-antibodies, n</td>
<td>Positive</td>
<td>55</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Negative</td>
<td>46</td>
<td></td>
</tr>
<tr>
<td>cGC dose (mg)</td>
<td></td>
<td>0 (0.0–5.0)</td>
<td>49</td>
</tr>
<tr>
<td>Actual GC dose at sampling (mg)</td>
<td>0 (0.0–5.0)</td>
<td>49</td>
<td>0.01</td>
</tr>
<tr>
<td>Patients taking GC at sampling, n</td>
<td>49</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Disease duration, years</td>
<td></td>
<td>4.76 (1.91–8.86)</td>
<td>75</td>
</tr>
<tr>
<td>Disease activity</td>
<td>Remission (CDAI &lt;2.8)</td>
<td>75</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>Low disease activity (CDAI 2.8–10)</td>
<td>20</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>High disease activity (CDAI &gt;10)</td>
<td>6</td>
<td>0.01</td>
</tr>
<tr>
<td>Bone status, n</td>
<td>Osteoporosis (T-score $&lt;-2.5$)</td>
<td>12</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>Osteopenia (T-score $-1.0$ to $-2.5$)</td>
<td>33</td>
<td>0.01</td>
</tr>
<tr>
<td></td>
<td>Not reported</td>
<td>18</td>
<td>0.01</td>
</tr>
</tbody>
</table>

Sclerostin, pmol/L

| PINP, ng/mL | 39.2 (29.6–50.7) | 34.0 (24.7–47.0) | 0.01 |
| Osteocalcin, ng/ml | 16.5 (12.3–22.3) | 10.6 (7.2–13.9) | 0.01 |
| CTX, ng/mL   | 0.26 (0.19–0.37) | 0.15 (0.08–0.27) | 0.01 |

For nominal variables n (%), for continuous variables median (1st–3rd quartile) are given.

*Chi-square test for nominal variables and Kruskal–Wallis test for continuous variables.

BMI, body mass index; CDAI, clinical disease activity score; cGC, cumulative Glucocorticoid dose; CRP, C-reactive Protein; CTX, carboxy-terminal telopeptide of type I collagen; GC, Glucocorticoid; MTX, Methotrexate; P1NP, intact amino-terminal propeptide of type I procollagen; RA, rheumatoid arthritis.
in women, acute inflammation defined as serum high-sensitivity C-reactive protein concentration >10 mg/L or pregnancy or were taking medications affecting bone metabolism (glucocorticoids, heparin, calcineurin inhibitors, anti-epileptic medication, bisphosphonates, parathyroid hormone, calcium, vitamin D preparations, selective estrogen receptor modulators).

The investigations in SHIP-1 as well as the investigation of the RA and PMR patients were carried out in accordance with the Declaration of Helsinki. Written informed consent was collected from all participants. The study methods were approved by the Institutional Review Board of the University of Greifswald and the Technische Universität Dresden, respectively.

Statistical analysis

Results are presented as means ± standard deviation (s.d.) or medians with 1st–3rd quartiles. All in vitro experiments were repeated at least three independent times. Statistical evaluations of two group comparisons were performed using a two-sided Student’s t-test. One-way ANOVA was used for experiments with more than two groups. Group differences in human samples were tested with chi-squared or Kruskal–Wallis tests. Correlations were analyzed using the Spearman correlation coefficient. P values <0.05 were considered statistically significant.

Results

Serum sclerostin levels are increased by endogenous and exogenous GC exposure in mice

To investigate the regulation of sclerostin in mice, we treated two different mouse strains with GCs. Effects on bone microstructure and bone histomorphometry were reported previously and showed a decrease of bone volume and bone formation parameters in the prednisolone-treated group of C57BL/6 mice (28). As expected, bone formation was suppressed in both GC-treated mouse strains as indicated by lower levels of the bone formation marker P1NP (Fig. 1A and B). Suppression of bone formation was already apparent after 10 days of treatment (Fig. 1B). Sclerostin serum concentrations were increased by 54% in C57BL/6 mice (P<0.05) and 52% in DBA/1 mice (P<0.01), respectively, compared to their untreated controls (Fig. 1A and B). To determine whether sclerostin is also upregulated in states of endogenous hypercortisolism, we investigated serum levels of sclerostin in mice with a gain-of-function point mutation in the

Table 2  Sclerostin in patients suffering from polymyalgia rheumatica (PMR) taking GC.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Controls</th>
<th>Cases</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Disease</td>
<td>PMR</td>
<td>21</td>
<td>21</td>
</tr>
<tr>
<td>Sex, n</td>
<td>Male</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Age, years</td>
<td>74.0 (72.0–76.0)</td>
<td>73.0 (72.0–75.0)</td>
<td>0.99</td>
</tr>
<tr>
<td>Current smokers, n</td>
<td>0</td>
<td>0</td>
<td>1.00</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>27.5 (24.4–28.6)</td>
<td>28.1 (24.8–29.3)</td>
<td>0.95</td>
</tr>
<tr>
<td>BMI categories, n</td>
<td>&lt;25 kg/m²</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>≥25–29 kg/m²</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>≥30 kg/m²</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>MTX, n</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CRP, mg/L</td>
<td>5.9 (2.05–14.75)</td>
<td>3300 (1850–8150)</td>
<td></td>
</tr>
<tr>
<td>cGC dose, mg</td>
<td>3.0 (2.9–7.5)</td>
<td>1.31 (0.42–4.22)</td>
<td></td>
</tr>
<tr>
<td>Actual GC dose at sampling, mg</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients taking GC at sampling, n</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Disease duration, years</td>
<td>1.31 (0.42–4.22)</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Bone status</td>
<td>Osteoporosis (T-score &lt;−2.5)</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Osteopenia (T-score −1.0 to −2.5)</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Not reported</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Sclerostin, pmol/L</td>
<td>70.6 (59.8–85.9)</td>
<td>51.9 (40.0–59.2)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>PINP, ng/mL</td>
<td>31.2 (21.8–61.2)</td>
<td>30.2 (19.8–43.8)</td>
<td>0.47</td>
</tr>
<tr>
<td>Osteocalcin, ng/mL</td>
<td>16.3 (10.1–26.7)</td>
<td>10.7 (5.5–15.1)</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>CTX, ng/mL</td>
<td>0.30 (0.17–0.53)</td>
<td>0.18 (0.05–0.23)</td>
<td>&lt;0.04</td>
</tr>
</tbody>
</table>

For nominal variables n (%), for continuous variables median (1st–3rd quartile) are given.
*Chi-square test for nominal variables and Kruskal–Wallis test for continuous variables.
BMI, body mass index; CDAI, clinical disease activity score; cGC, cumulative Glucocorticoid dose; CRP, C-reactive Protein; CTX, carboxy-terminal telopeptide of type I collagen; GC, Glucocorticoid; MTX, Methotrexate; P1NP, intact amino-terminal propeptide of type I procollagen; PMR, polymyalgia rheumatica.
corticotropin-releasing hormone, leading to excessive levels of corticosterone. These mice displayed typical features of Cushing’s syndrome including obesity, thin skin, muscle wasting and bone loss. Inhibited bone formation was verified in this model, detecting low P1NP serum levels in mice with endogenous hypercortisolism (Fig. 1C). In addition, serum levels of sclerostin were increased by 26% (*P < 0.05) (Fig. 1C). Thus, these data suggest that treatment with synthetic GCs as well as endogenous GC exposure both increased systemic sclerostin levels in mice.

**Regulation of sclerostin after GC treatment ex vivo and in vitro**

After having established that GC treatment increases sclerostin systemically, we asked whether the induction of *Sost* is also seen *ex vivo* or *in vitro* in femoral tissue of treated mice. Therefore, we isolated RNA from femora of GC-treated C57BL/6 mice. However, *Sost* expression was not regulated consistently in four independent experiments (Fig. 2A, B, C and D). Despite using the same mouse strain (C57BL/6 mice), age, sex, GC dose and treatment duration, *Sost* was increased three-fold (*P < 0.05) in the first experiment, whereas two other experiments displayed a trend towards reduced *Sost* mRNA expression (Fig. 2G). Similarly, also the third and fourth experiment did not show a consistent regulation (Fig. 2H and I) and again, pooling of normalized data displays a trend of increased *Sost* expression without significant differences (Fig. 2J). *Sost* expression was also not consistently regulated in the osteocytic cell lines Ocy454 and IDG-SW3 (data not shown). Taken together, despite the induction of serum levels of sclerostin, its expression is not consistently regulated in femoral bone tissue or in osteogenic cell cultures.

**Sclerostin expression is decreased after GC treatment in human bone marrow stromal cells**

To examine if sclerostin is regulated in human cells, we went on to investigate the influence of GCs on the expression of *SOST* in hMSC. Therefore, we treated hMSC with different doses of DEX for 24, 48 and 72 h. DEX treatment led to a significant dose- and
time-dependent decrease of \textit{SOST} mRNA levels reaching a maximum suppression after 48 h at a concentration of 10 \mu M (Fig. 3A and B). These results were confirmed at protein level (Fig. 3C and D). In addition, the osteoblast-inhibiting properties of DEX were demonstrated by examining the expression of osteocalcin, which was also dose- and time-dependently decreased (Bone gamma-carboxyglutamate protein \textit{BGLAP}/osteocalcin; Fig. 3E and F). As shown previously, these concentrations of DEX did not affect cell viability (26).

**Sclerostin expression depends on the presence of the GR**

We next set out to investigate whether the down-regulation of \textit{SOST} by GCs is GR dependent. To investigate the regulation of \textit{SOST} by the GR, we overexpressed the GR in hMSC using pCMX-hGR, which resulted in a nine-fold increased mRNA expression of the GR (\textit{NR3C1}; Fig. 4A). Furthermore, we found a three-fold higher mRNA expression of \textit{SOST} in hMSC after transfection with pCMX-hGRa indicating an important role of the GR for \textit{SOST} expression. DEX treatment reduced mRNA levels of \textit{SOST} by 75\% in control cells and decreased \textit{SOST} in GR-overexpressing hMSCs even further by 98\% (\textit{P}<0.01; Fig. 4B).

Furthermore, we knocked-down GR expression in hMSC using siRNA. GR (\textit{NR3C1}) mRNA expression was downregulated by 83\% (\textit{P}<0.01) compared to control-treated cells (Fig. 4C). Interestingly, while DEX treatment decreased \textit{SOST} mRNA expression by 87\% (\textit{P}<0.01), also GR knockdown itself reduced \textit{SOST} expression, suggesting that basal \textit{SOST} expression depends on the GR (\textit{\sim}90\%; \textit{P}<0.01; Fig. 4D).

**Low sclerostin serum concentrations in patients taking glucocorticoids**

To further define the role of sclerostin in a human setting, we analyzed 122 patients who had previously received GCs to treat their disease. Those patients had either RA or PMR and were compared to healthy individuals matched for age, sex, smoking status and BMI. PMR was specifically chosen as those patients initially receive high doses of GCs. Patient characteristics are shown in Tables 1 and 2. At the time point of sampling, about half of the RA patients currently received GC, while all but one PMR patient were on GC treatment (Tables 1 and 2). Serum levels of sclerostin were decreased by 40\% (\textit{P}<0.01) in RA patients taking GC and by 27\% (\textit{P}<0.01) in PMR patients taking GC compared to matched controls (Tables 1 and 2). This was accompanied by decreased bone formation, indicated by...
decreased levels of osteocalcin, as well as a decrease in the bone resorption marker CTX in both cohorts, indicating reduced bone remodeling in GC-treated patients (Tables 1 and 2). Bone turnover markers in PMR patients were not affected as much as in patients with RA (Tables 1 and 2). Thus, these results suggest that the intake of GCs leads to decreased sclerostin serum levels.

Discussion

Osteoporosis is one of the most common and serious side effects of GC treatment as up to 50% of GC-treated patients experience osteoporotic fractures (3, 20). Previous studies have shown that the suppression of Wnt signaling may be a key mechanism for the development of GIO. Here, we investigated the regulation of sclerostin, an important inhibitor of Wnt signaling, in mice and humans exposed to high levels of GCs. Our data showed that sclerostin is increased in the serum of mice with high endogenous or exogenous GC levels. However, its expression is not clearly regulated in bone tissue or murine BMSCs treated with GCs. In contrast, sclerostin levels are suppressed in human MSCs stimulated with GCs and in RA and PMR patients requiring GC therapy.

Contradictory results are found when searching for the regulation of sclerostin by GCs in the literature. A previous study had shown that mice implanted with...
prednisolone pellets displayed increased serum sclerostin levels after 42 days. However, after 28 days no significant difference was found. Furthermore, Sost expression was transiently increased in calvarial osteoblasts after 12-h treatment with DEX, but not after 6 or 24 h (11). Also, increased Sost expression in the skeleton was found after 4 weeks of GC treatment in C57BL/6 mice (12). In contrast, skeletal Sost expression was not different after GC treatment of Swiss Webster mice (13) or Sprague–Dawley rats (14). Even though our study showed increased serum levels of sclerostin in three different models of high GC levels, skeletal expression was not different and also treating various osteogenic cells with GC did not regulate Sost expression. This raises the question if other cells than osteogenic cells may contribute to increased systemic levels of sclerostin after GC treatment in mice. In fact, also vascular smooth muscle cells (29) or periodontal ligament cells (30) have been shown to express Sost, albeit at lower levels as osteocytes. While different dosages, time intervals and mouse strains may account for some of the differences in results, overall, sclerostin does not seem to be consistently regulated by GCs in mice.

Despite the lack of clear regulation of sclerostin by GCs in mice, studies have investigated the potential of sclerostin-neutralizing antibodies for the treatment of GC-induced bone loss. A recent study demonstrated that mice lacking Sost are protected from GC-induced bone loss. Surprisingly, this was not mediated by rescuing the GC-induced decrease in bone formation, but via its anti-catabolic activity (12). Furthermore, treatment with sclerostin-neutralizing antibodies increased bone mass and strength in mouse models of GIO (31, 32). However, it should be noted that, even though animals treated with sclerostin antibodies displayed an overall higher bone volume, they lost even more bone after GC treatment than control animals suggesting that sclerostin does not play a major pathogenic role in GIO (32).

In contrast to our mouse studies, the regulation of sclerostin appeared more consistent in the human system as sclerostin was decreased after GC treatment in human bone marrow stromal cells. This regulation is

Figure 4
Sclerostin (SOST) expression depends on the presence of the glucocorticoid receptor (GR). The GR was overexpressed in human mesenchymal stromal cells (hMSCs) using pCMX-HA-hGRalpha and then left untreated or treated with dexamethasone (DEX; 0.1 and 1 µM) for 48 h. The GR was knocked-down in hMSCs using siRNA and then left untreated or treated with DEX (0.1 µM) for 48 h. SOST (B, D) and NR3C1 (GR; A, C) gene expression levels were determined using qPCR. n = 4; *P < 0.05; **P < 0.01; ***P < 0.001 vs CO; ##P < 0.01 vs siCO.
most likely dependent on classical GR signaling as hMSCs treated with siGR and DEX did not show reduced SOST expression. In line with this, the SOST promoter contains several GC response elements, making it amenable to GC actions (11).

After showing that GC treatment decreased sclerostin expression in human cells we went on to investigate its concentration in sera of patients taking GCs. Sclerostin was markedly decreased in both cohorts of patients receiving GC therapy. Two other larger studies with 80 and 91 patients, respectively, showed decreased serum sclerostin concentrations after GC treatment of patients with chronic inflammatory diseases (33, 34). In addition, sclerostin was decreased after 96 h of GC treatment as compared to before GC treatment (35). Only one study reported increased levels of sclerostin after 1-year GC therapy (>7.5 mg/day), although the increase was rather small (36). Of note, this is the only study that investigated patients with hematological disorders (n=25) (36), indicating that the underlying diseases may also contribute to alterations in serum sclerostin levels. A differential regulation of sclerostin has also been reported in patients with hypercortisolism. While one study described lower levels of sclerostin in patients with endogenous hypercortisolism compared to healthy controls (37), another study found higher sclerostin levels (38, 39). However, diverse approaches for example different time points for taking the blood samples or collection of non-fasting versus fasting blood samples as well as the study populations themselves or the method used to determine the sclerostin level in the blood was different in the studies and may account for the differences in the results (37). Interestingly, not only bone formation parameters were low in our patient cohorts, but also bone resorption. As almost all patients received additional treatments during the time of blood sampling, these may have resulted in reduced inflammation but also reduced bone turnover.

Our study has potential limitations. First, different mouse strains were investigated albeit studies have shown that different mouse strains react distinctly to GC treatment in terms of bone loss (9, 40). Nonetheless, all mouse strains in this study showed suppressed bone formation parameters upon GC treatment, suggesting a robust and uniform mechanism of GC-mediated suppression of bone formation. Second, even though our patient cohorts were homogenous in terms of underlying disease, two-thirds of the RA patients were treated with DMARDs and half of the RA patients did not receive GC treatment at the time of sampling. However, in the PMR cohort, only two patients had an additional treatment with MTX, and all but one received GC at the time of blood analysis, suggesting that the observed effects on sclerostin levels should stem from the GC treatment. Moreover, it is not possible to perfectly distinguish between the effects of disease activity vs GC on sclerostin levels, and we could not correlate serum sclerostin levels with bone mineral density, as this parameter was not available for all patients. Nonetheless, suppression of bone formation appears to be a more sensitive marker for reflecting the negative effects of GC on bone.

Taken together this study shows that sclerostin is differentially regulated by GCs in mice and humans. While sclerostin serum levels are increased after GC administration in mice, its mRNA expression in murine BMSCs is not regulated. In contrast, sclerostin is decreased in human MSCs stimulated with GCs as well as in patients taking GCs suggesting that GC-induced bone loss is not primarily driven via sclerostin.

Declaration of interest
MR is a senior editor for Endocrine Connections. She was not involved in the editorial or peer review process for this paper, on which she is listed as an author. The other authors have nothing to disclose.

Funding
This work was supported by the European Calcified Tissue Society, the MedDrive start-up grant from the TU Dresden to S T and grants from the Deutsche Forschungsgemeinschaft to S T, L C H, and M R. R V T is supported by Medical Research Council UK (grant numbers G9825289 and G1000467) and a Welcome Trust Investigator Award. M R is supported by the Support-the-Best Initiative of the TUD funded through the Excellence initiative of the German Federal and State Governments.

Author contribution statement
S T, A H, L C H and M R contributed to the study conception and design. S T, M W, U B, H W, M N, R V T, M B, A H and M R collected data and performed data analysis. Data were interpreted by S T, A H, U B, H W, M W, M N, R V T, M B, L C H and M R. S T, and M R drafted the manuscript. All authors critically revised the content of the manuscript and approved its final version. M R takes responsibility for the integrity of the data analysis.

Acknowledgements
The authors would like to thank Liz Bentley and Roger Cox from MRC Harwell Institute, Mammalian Genetics Unit, Harwell Campus, Oxfordshire, UK, for providing serum samples of Crh<sup>−/−</sup> mice.

References
1 Hofbauer LC & Rauner M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Molecular Endocrinology 2009 23 1525–1531. (https://doi.org/10.1210/me.2009-0069)
Sclerostin regulation by glucocorticoids

S Thiele et al.


7 Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, Ross FP & Teitelbaum SL. Protection from glucocorticoid-induced osteoporosis. Bone Research 2017 5 149. (https://doi.org/10.1172/JCI2799)

8 Hofbauer LC, Gori I, Riggia BI, Lacey DI, Dunstan CR, Spelsberg TC & Khosla S. Stimulation of osteoprotegrin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999 140 4382–4389. (https://doi.org/10.1210/endo.140.10.7034)


11 Beier EE, Sheu TJ, Ressegue EA, Takahata M, Awad HA, Cory-Slechta DA & Puzas JE. Sclerostin activity plays a key role in the negative effect of glucocorticoid signaling on osteoblast function in mice. Bone Research 2017 5 1703. (https://doi.org/10.1038/boneres.2017.13)


Sclerostin regulation by glucocorticoids


34. Braz NFT, Rocha NP, Vieira ÉLM, Gomez RS, Barbosa IG, Malheiro OB, Kakehashi AM & Teixeira AL. Negative impact of high cumulative glucocorticoid dose on bone metabolism of patients with myasthenia gravis. *Neurological Sciences* 2017 38 1405–1413. (https://doi.org/10.1007/s10072-017-2964-z)


Received in final form 4 June 2019
Accepted 11 June 2019
Accepted Preprint published online 11 June 2019